| Title |
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
|
|---|---|
| Published in |
Leukemia, January 2019
|
| DOI | 10.1038/s41375-019-0384-1 |
| Pubmed ID | |
| Authors |
Shaji K. Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, S. Vincent Rajkumar, Paul G. Richardson |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Spain | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 16% |
| Other | 11 | 14% |
| Student > Ph. D. Student | 7 | 9% |
| Professor > Associate Professor | 4 | 5% |
| Student > Doctoral Student | 4 | 5% |
| Other | 16 | 21% |
| Unknown | 22 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 46% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Engineering | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 10 | 13% |
| Unknown | 23 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 93. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2022.
All research outputs
#463,218
of 25,653,515 outputs
Outputs from Leukemia
#60
of 5,467 outputs
Outputs of similar age
#10,578
of 449,428 outputs
Outputs of similar age from Leukemia
#4
of 105 outputs
Altmetric has tracked 25,653,515 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,467 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.